Comparative Pharmacology
Head-to-head clinical analysis: ANZUPGO versus ARSENIC TRIOXIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANZUPGO versus ARSENIC TRIOXIDE.
ANZUPGO vs ARSENIC TRIOXIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not established; no known pharmacological mechanism due to lack of clinical data.
Arsenic trioxide induces apoptosis in acute promyelocytic leukemia (APL) cells through degradation of PML-RARα fusion protein and modulation of mitochondrial pathways.
Not available. ANZUPGO is not a recognized drug in medical literature.
0.15 mg/kg IV daily until remission, then 0.15 mg/kg IV 5 days per week for 5 weeks (consolidation); dose based on actual body weight.
None Documented
None Documented
Terminal elimination half-life is 2.5-3.0 hours; clinically, this supports intravenous administration every 6-8 hours for continuous coverage.
Clinical Note
moderateArsenic trioxide + Digoxin
"Arsenic trioxide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateArsenic trioxide + Digitoxin
"Arsenic trioxide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateArsenic trioxide + Deslanoside
"Arsenic trioxide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateArsenic trioxide + Acetyldigitoxin
Terminal elimination half-life of inorganic arsenic is approximately 10–14 hours for the trivalent form, but for total arsenic (including methylated metabolites) the half-life ranges from 10 to 32 hours. Clinical context: due to extensive tissue distribution and metabolic conversion, the effective half-life for pharmacodynamic effect is prolonged, with repeated dosing leading to accumulation. The terminal half-life is biphasic: an initial distribution phase of about 2 hours and a terminal phase of 10–14 hours.
Renal excretion of unchanged drug accounts for 70-80%; biliary/fecal elimination constitutes the remainder (20-30%).
Primarily renal excretion; after intravenous administration, approximately 15% of the dose is excreted unchanged in urine over 24 hours. Biliary/fecal excretion accounts for less than 5% as unchanged drug; the majority is eliminated as methylated metabolites (monomethylarsonic acid and dimethylarsinic acid) via urine, with total urinary excretion of arsenic species reaching 60-85% of the dose within 14 days.
Category C
Category C
Antineoplastic
Antineoplastic
"Arsenic trioxide may decrease the cardiotoxic activities of Acetyldigitoxin."